Teva Pharmaceutical Industries, Ltd., has been trying to buy fellow giant generic drugmaker Mylan, Inc., and the latest step to emerge was the purchase of chunks of stock on the open market. Teva said it had bought a 1.35% stake in …
Mylan’s stock price surged after their price increase strategy, going from as low as $14.84 per share in 2007, when it first bought EpiPens, to as high as $49.09 on Monday. Attention given to the rising price of the pens has prompted calls …
Yet not all stockholders were aware of the tax implications. John Kablach, 85, of Smithton only recently found out he would have to pay capital gains on his Mylan stock, which he's owned since the mid-1980s. The retired melt shop supervisor …
Mylan's shares dropped after it said that delays in launching key new drugs and lower prices for generics in the United States will hurt its profitability this and next year. Fred Katayama reports. Mylan's stock plunged after the maker of Epi …
But instead she can now add some shadily-timed trading of Mylan stock to her growing list of “Things That Suck For Me Right Now.” Heather Bresch, the CEO at the center of EpiPen’s 471% price hike, sold 100,200 of her shares earlier this …
It noted that the company's market capitalization has swelled to more than $20 million from about $3 million over the last 15 years, and its stock price also has soared over the longer time frame. "During Mr. Coury's long tenure, Mylan has …
Through Thursday’s close, Mylan’s stock had lost about 37 percent of its value since it made public its offer to acquire Perrigo on April 8. Changes to Mylan stock price account for part of the change in total deal value. Following is a …
What a difference a hostile takeover bid can make. Perrigo Co. for months has been publicly trashing Mylan NV and its prospects as part of an effort to fend off a roughly $27 billion hostile bid from the Dutch company. But the concerns …
PITTSBURGH – Generic drug maker Mylan Laboratories Inc. (MYL) is buying branded drug maker King Pharmaceuticals Inc. (KG) for about $4 billion in stock, company officials said Monday. Mylan has pursued a stronger position in the …
Shareholders of the drugmaker Perrigo have shut the door on a $26-billion hostile takeover bid from Mylan. Mylan said that its cash-and-stock offer failed to garner enough interest from Perrigo shareholders by a Friday morning deadline to …